Clinical trialPhase 1 / Phase 2Not yet recruiting
JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure
A Phase Ib/II Clinical Trial of JDB153 Combined With Serplulimab for the Treatment of Pancreatic Cancer Refractory to Standard Therapy
- Outcome
- Ongoing
- Phase
- Phase 1 / Phase 2
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 1 September 2026
- Expected end
- 1 December 2028
- Enrollment
- 10 participants
- Sites
- 1
- Primary outcomes
- Incidence of Treatment-Related Adverse Events; Objective Response Rate (ORR)
- Sponsor
- Other
- Results posted
- No
- Last update
- 19 August 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The goal of this clinical trial is to evaluate the safety and efficacy of JDB153 combined with Serplulimab in patients with pancreatic cancer after standard treatment failure.
Detailed description public domain (ClinicalTrials.gov)
This study is a single-arm, single-center, exploratory clinical trial aimed at evaluating the safety and efficacy of JDB153 combined with Serplulimab in patients with pancreatic cancer after standard treatment failure.